The prevalence of human immunodeficiency virus type 1 and hepatitis C virus among injection drug users who use high risk inner-city locales in Miami, Florida

Memorias do Instituto Oswaldo Cruz

Volumn 99, Issue 8, 2004, Pages 789-793

  McCoy, Clyde B ^a   Metsch, Lisa R ^a   Collado Mesa, Fernando ^a   Arheart, Kristopher L ^a   Messiah, Sarah E ^a   Katz, Dolores ^b   Shapshak, Paul ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FLORIDA DEPARTMENT OF HEALTH   (United States)

Author keywords

Co infection; Hepatitis C virus; Human immunodeficiency virus 1; Injection drug users

Indexed keywords

DIAMORPHINE;

ADULT; ARTICLE; CITY; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; UNITED STATES; WESTERN BLOTTING;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 13844266544     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762004000800002     Document Type: Article

References (22)

1. Alter MJ, Moyer LA 1998. The importance of preventing hepatitis C virus infection among injection drug users in the United States. JAIDS 18: S6-10.
2. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T 1999. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30: 1054-1058.
3. CDC-Centers for Disease Control and Prevention 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 47: 1-39.
4. de Carvalho HB, Mesquita F, Massad E, Bueno RC, Lopes GT, Ruiz MA, et al. 1996. HIV and infections of similar transmission patterns in a drug injectors community of Santos, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol 12: 84-92.
5. Edeh J, Spalding P 2000. Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England. J Public Health Med 22: 531-539.
6. Hosmer DW, Lemeshow S 2000. Applied Logistic Regression, 2nd ed., John Wiley & Sons, New York, p. 392-403.
7. Lamden KH, Kennedy N, Beeching NJ, Lowe D, Morrison CL, Mallinson H, Mutton KJ, Syed Q 1998. Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. J Infect 37: 260-269.
8. Maier I, Wu GY 2002. Hepatitis C and HIV co-infection: a review. World J Gastroenterol 8: 577-579.
9. Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, Gunther S 2001. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 32: 144-148.
10. Marmor M, Des Jarlais DC, Cohen H, Friedman SR, Beatrice ST, Dubin N, el-Sadr W, Mildvan D, Yancovitz S, Mathur U 1987. Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS 1: 39-44.
11. McCoy CB, Shapshak P, Metsch LR, Rivers JE, McCoy HV, Weatherby NL, Shah SM, Chitwood DD 1995. HIV-1 prevention: interdisciplinary studies on the efficacy of bleach and development of prevention protocols. Review. Arch Immunol Ther Exp (Warsz) 43: 1-9.
12. Mendes-Correa MC, Barone AA, Guastini C 2001. Hepatitis C virus seroprevalence and risk factors among patients with HIV infection. Rev Inst Med Trop São Paulo 43: 15-19.
13. Merrik ST, Sepkowitz SA, Boyle BA, Jacobs JL 1998. Seroprevalence of hepatitis C antibody and hepatitis B surface antigenemia in a large urban HIV clinic. Abstract 22263. XII International Conference on AIDS, Geneva.
14. Proietti F, Caiaffa W, Carneiro-Proietti AB, et al. 2000. Seroprevalence correlates of HIV and HCV infection among injection drug users (IDUs) attending an outreach syringe exchange program (SEPs) in five Brazilian cities. Abstract WeOrA530. XIII International Conference on AIDS, Durban.
15. Robinson P 1998. Sharps injuries in dental practice. Prim Dent Care 5: 33-39.
16. Samuel MC, Doherty PM, Bulterys M, Jenison SA 2001. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 127: 475-484.
17. Saves M, Raffi F, Clevenbergh P, Manchou B 2000. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. Antimicro Agents Chemo 44: 3451-3455.
18. Schoenbaum EE, Hartel D, Selwyn PA, Klein RS, Davenny K, Rogers M, Feiner C, Friedland G 1989. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med 321: 874-879.
19. Thomas DL, Shih JW, Alter HJ, Vlahov D, Conn S, Hoover DR, Cheung L, Nelson KE 1996. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 174: 690-695.
20. Van Beek I, Buckely R, Stewart M, MacDonald M, Kaldor J 1994. Risk factors for hepatitis C infection among injection drug users in Sydney. Genitourinary Medicine 70: 321-324.
21. Zaric GS, Barnett PG, Brandeau ML 2000. Methadone maintenance and HIV prevention: a cost-effectiveness analysis. Am J Public Health 90: 1-12.
22. Zylberberg H, Nalpas B, Pol S 2001. Is there a relationship between hepatitis C virus infection and antiretroviral lipoatrophy? AIDS 14: 2055-2065.